Joshua Richter, MD, Talks Results From LINKER-MM1 Study

Dr. Richter of the Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai, joins Blood Cancers Today from the 20th International Myeloma Society Annual Meeting and Exposition to discuss data from the phase II LINKER-MM1 study.

He spoke about his poster presentation, which focused on the evaluation of the efficacy and safety of two linvoseltamab dosing regimens, 50 mg and 200 mg.

The study evaluated the two doses in patients with multiple myeloma who were “heavily pretreated” and have “progressed beyond our standard novel agents,” Dr. Richter said.

He highlighted key findings from the study.

“Overall, the immediate safety issues, things like cytokine release [syndrome], seem to be very, very impressive in the study population,” he said. “From an efficacy standpoint, this is where we really see distinct advantages of the 200 milligram dose over the 50 milligram dosing.”

He also spoke about a phase III study of the drug, evaluating linvoseltamab combinations, and what he sees as the next steps with the line of research.